Focusing pharmacoeconomic activities: Reimbursement or the drug life cycle?

Current Medical Research and Opinion

Volumn 20, Issue 2, 2004, Pages 181-188

  Langley, Paul C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

AMCP guidelines; Business opportunity assessment; Class reviews; Drug development; Drug life cycle; NICE guidelines; Reimbursement

Indexed keywords

DRUG;

CLINICAL TRIAL; COMMERCIAL PHENOMENA; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; REIMBURSEMENT; REVIEW;

AUSTRALIA; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG EVALUATION; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; FORMULARIES; GUIDELINES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT;

EID: 1042268094     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002838     Document Type: Review

References (12)

1. Australia. Department of Health Housing and Community Services. Guidelines for the pharmaceutical industry on the preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: AGPS, 1992
2. Australia. Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: September, 2002
3. United Kingdom. National Institute for Clinical Excellence. Guidelines for manufacturers and sponsors. Technology Appraisal series No. 5. London: NICE, June 2001
4. United Kingdom. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal (Consultation draft, August 2003)
5. Langley PC, Martin RE, Burton E. Guidelines for Formulary Submission. Integrated Pharmaceutical Services and Foundation Health Corporation, Rancho Cordova, CA, October 1966
6. Regence Washington Health Pharmacy Services. Guidelines for the submission of clinical and economic data supporting formulary consideration. Regence Washington Health, University of Washington, Seattle 1997
7. Langley PC. Guidelines for formulary submissions for pharmaceutical product evaluation. Blue Cross and Blue Shield of Colorado and Nevada. Denver CO, October 1998
8. Academy of Managed Care Pharmacy. Format for Formulary Submissions Version 2.0. AMCP, October 2002
9. DiMasi JA, Caglarcan E, Wood-Armany M. Emerging role of pharmacoeconomics in the research and development decision-making process. Pharmacoeconomics 2001;19:753-66
10. DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001;69:297-307
11. DiMasi JA. The value of improving the productivity of the drug development process. Pharmacoeconomics 2002;20 (Suppl 3):1-10
12. Langley PC. Health Economics in the Drug Life Cycle. London: Urch Publishing, 2002